Scholarlink

Study Objectives: <p>To assess the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in the treatment of obstructive sleep apnea.</p> Methods: <p>A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity.</p> Results: <p>Emerging evidence indicates that SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are beneficial for treating obesity in combination with sleep apnea. Although these medications have shown promise in weight reduction, with GLP-1 receptor agonists slightly outperforming SGLT2 inhibitors, their effect on sleep apnea extends beyond mere weight loss. Preliminary studies suggest a beneficial role in obstructive sleep apnea management with reductions in the apnea-hypopnea index and potential improvements in other sleep-related outcomes.</p> Conclusions: <p>There is a need for more therapeutic options to treat sleep apnea as adherence with current treatment options remains a struggle for many patients. According to preliminary research, SGLT2 inhibitors, GLP-1 and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnia index and weight. Nevertheless, large-scale clinical trials are needed to assess their clinical potential and risk balance in more detail.</p> Citation: <p>Sevencan B, Steenackers N, van Laar ADE, et&#xa0;al. Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review. <i>J Clin Sleep Med</i>. 2025;21(8):1433–1444.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review

  • 期刊论文

  • 发表日期：

    2025年8月1日

查看全文
  • Beyza Sevencan,
  • Nele Steenackers,
  • Amar Daniël Emanuel van Laar,
  • Sofía Pazmiño Lucio,
  • Bertien Buyse,
  • Alexandros Kalkanis,
  • Dries Testelmans,
  • Bart Van der Schueren

摘要

Study Objectives:

To assess the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in the treatment of obstructive sleep apnea.

Methods:

A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity.

Results:

Emerging evidence indicates that SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are beneficial for treating obesity in combination with sleep apnea. Although these medications have shown promise in weight reduction, with GLP-1 receptor agonists slightly outperforming SGLT2 inhibitors, their effect on sleep apnea extends beyond mere weight loss. Preliminary studies suggest a beneficial role in obstructive sleep apnea management with reductions in the apnea-hypopnea index and potential improvements in other sleep-related outcomes.

Conclusions:

There is a need for more therapeutic options to treat sleep apnea as adherence with current treatment options remains a struggle for many patients. According to preliminary research, SGLT2 inhibitors, GLP-1 and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnia index and weight. Nevertheless, large-scale clinical trials are needed to assess their clinical potential and risk balance in more detail.

Citation:

Sevencan B, Steenackers N, van Laar ADE, et al. Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review. J Clin Sleep Med. 2025;21(8):1433–1444.